Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients
Margherita Rimini,Mara Persano,Toshifumi Tada,Goki Suda,Shigeo Shimose,Masatoshi Kudo,Jaekyung Cheon,Fabian Finkelmeier,Ho Yeong Lim,José Presa,Francesca Salani,Sara Lonardi,Fabio Piscaglia,Takashi Kumada,Naoya Sakamoto,Hideki Iwamoto,Tomoko Aoki,Hong Jae Chon,Vera Himmelsbach,Marta Schirripa,Margarida Montes,Caterina Vivaldi,Caterina Soldà,Atsushi Hiraoka,Takuya Sho,Takashi Niizeki,Naoshi Nishida,Christoph Steup,Masashi Hirooka,Kazuya Kariyama,Joji Tani,Masanori Atsukawa,Koichi Takaguchi,Ei Itobayashi,Shinya Fukunishi,Kunihiko Tsuji,Toru Ishikawa,Kazuto Tajiri,Hironori Ochi,Satoshi Yasuda,Hidenori Toyoda,Chikara Ogawa,Takashi Nishimura,Takeshi Hatanaka,Satoru Kakizaki,Noritomo Shimada,Kazuhito Kawata,Fujimasa Tada,Hideko Ohama,Kazuhiro Nouso,Asahiro Morishita,Akemi Tsutsui,Takuya Nagano,Norio Itokawa,Tomomi Okubo,Taeang Arai,Michitaka Imai,Hisashi Kosaka,Atsushi Naganuma,Yohei Koizumi,Shinichiro Nakamura,Masaki Kaibori,Hiroko Iijima,Yoichi Hiasa,Valentina Burgio,Mario Scartozzi,Stefano Cascinu,Andrea Casadei-Gardini
DOI: https://doi.org/10.1007/s00432-023-04678-2
2023-03-28
Journal of Cancer Research and Clinical Oncology
Abstract:IntroductionThe best first-line treatment for patients with advanced hepatocellular carcinoma (HCC) and Child–Pugh (CP) class B remains unknown. The aim of the present study was to perform a real-world analysis on a large sample of patients with unresectable HCC with CP B treated with atezolizumab plus bevacizumab Vs Lenvatinib.MethodsThe study population included patients affected by advanced (BCLC-C) or intermediate (BCLC-B) HCC patients not suitable for locoregional therapies from both the Western and Eastern world (Italy, Germany, Republic of Korea and Japan), who received atezolizumab plus bevacizumab or Lenvatinib as first-line treatment. All the study population presented a CP class of B. The primary endpoint of the study was the overall survival (OS) of CP B patients treated with Lenvatinib compared to atezolizumab plus bevacizumab. Survival curves were estimated using the product-limit method of Kaplan–Meier. The role of stratification factors was analyzed with log-rank tests. Finally, an interaction test was performed for the main baseline clinical characteristics.Results217 CP B HCC patients were enrolled in the study: 65 (30%) received atezolizumab plus bevacizumab, and 152 (70%) received lenvatinib. The mOS for patients receiving Lenvatinib was 13.8 months (95% CI: 11.6–16.0), compared to 8.2 months (95% CI 6.3–10.2) for patients receiving atezolizumab plus bevacizumab as first-line treatment (atezolizumab plus bevacizumab Vs Lenvatinib: HR 1.9, 95% CI 1.2–3.0, p = 0.0050). No statistically significant differences were highlighted in terms of mPFS. The multivariate analysis confirmed that patients receiving Lenvatinib as first-line treatment have a significantly longer OS compared to patients receiving atezolizumab plus bevacizumab (HR 2.01; 95% CI 1.29–3.25, p = 0.0023). By evaluating the cohort of patients who received atezolizumab plus bevacizumab, we found that Child B patients with ECOG PS 0, or BCLC B stage or ALBI grade 1 were those who had benefited from the treatment thus showing survival outcomes no significantly different compared to those receiving Lenvatinib.ConclusionThe present study suggests for the first time a major benefit from Lenvatinib compared to atezolizumab plus bevacizumab in a large cohort of patients with CP B class HCC.
oncology